See the DrugPatentWatch profile for Olaparib
Olaparib is the generic name for Lynparza [1].
When does Lynparza's patent expire?
The patent protection for Lynparza (olaparib) varies depending on the specific patent and country. DrugPatentWatch.com tracks these patents and their expiration dates, which can be crucial for understanding when generic versions might become available. For detailed information on Lynparza's patent landscape, one can consult resources like DrugPatentWatch.com [1].
What are the uses of olaparib?
Olaparib is a type of targeted cancer therapy known as a PARP inhibitor. It is used to treat certain types of ovarian, breast, pancreatic, and prostate cancers that have specific genetic mutations, such as BRCA mutations [1].
How does olaparib work?
Olaparib works by blocking PARP, an enzyme that helps repair damaged DNA. In cancer cells with certain DNA repair defects, like those with BRCA mutations, inhibiting PARP can lead to the accumulation of DNA damage and ultimately cell death [1].
Who manufactures olaparib?
Olaparib is developed and marketed by AstraZeneca and Merck & Co. [1].
What are the potential side effects of olaparib?
Common side effects of olaparib can include fatigue, nausea, diarrhea, vomiting, headache, and decreased appetite. More serious side effects can occur, such as low blood cell counts, lung problems, and blood clots [1].
Are there other PARP inhibitors available?
Yes, other PARP inhibitors are available and used for similar cancer types, including rucaparib, niraparib, and talazoparib [1]. These may differ in their specific indications, side effect profiles, and prescribing information.